Login to Your Account



Financings Roundup

Nektar Selling 19M Shares as Firm Goes Solo on NKTR-102

By Jennifer Boggs


Thursday, January 20, 2011
A week after President and CEO Howard W. Robin told investors at the J.P. Morgan Healthcare Conference in San Francisco that Nektar Therapeutics Inc. planned to move into Phase III on its own with cancer drug NKTR-102, the firm priced a hefty public offering to bolster its cash reserves.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription